MedTrace Logo

Phenolic Complex k110-42 Therapy on Cognitive Functions in Down Children

NCT07284693 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-12-16

No results posted yet for this study

Summary

The goal of this study is to evaluate the efficacy of phenolic complex k110-42 on cognitive function of children with Down syndrome

Conditions

  • Cognitive Functions

Interventions

DRUG

Phenolic complex k110-42

900 mg/kg once oral in form of sachet for 6 month

DRUG

Neumentix

0 mg/kg once sachet oral for 6 month

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-07-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07284693 on ClinicalTrials.gov